This invention relates to methods for producing a transgenic C. elegans that
expresses a human 7TMR pan-neuronally, such that said transgenic C. elegans
exhibits a known phenotype. These transgenic C. elegans can be used
in a variety of ways, including, but not limited to: (1) screening and identifying
substances that bind to and activate particular human 7TMRs; (2) screening for
substances that antagonize human 7TMR activation; (3) identifying human 7TMRs that
may respond to particular substances; and (4) evaluating the specificity and efficacy
of substances on human 7TMR activation.
